株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

泌尿生殖器用薬剤市場 - 成長、傾向、および予測

Genitourinary Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 871435
出版日 ページ情報 英文 113 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
泌尿生殖器用薬剤市場 - 成長、傾向、および予測 Genitourinary Drugs Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年06月01日 ページ情報: 英文 113 Pages
概要

当レポートでは世界の泌尿生殖器用薬剤市場について調査しており、市場概況や成長要因・阻害要因、病気の種類・薬の種類・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報をまとめています。

目次

第1章 イントロダクション

  • 研究成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概況
  • 市場成長要因
    • 泌尿生殖器疾患の罹患率の増加
    • 可処分所得の増加と医療インフラの絶え間ない改善
    • 増加するパイプライン製品
  • 市場の阻害要因
    • 治療コンプライアンスの欠如
    • 偽造医薬品出現の増加
  • ポーターファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 業界内の競争

第5章 市場セグメント

  • 病気の種類別
    • 勃起不全
    • 淋病
    • 性器ヘルペス
    • 尿路感染症
    • 尿失禁
    • 糸球体腎炎
    • 慢性腎不全
    • その他
  • 薬の種類別
    • 調和療法
    • インポテンツ剤
    • 子宮弛緩薬
    • 鎮痙薬
    • 尿pH調整剤
    • 子宮刺激薬
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東およびアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Bristol-Myers Squibb Co.
    • Eli Lilly and Company
    • GlaxoSmithKline
    • Achaogen, Inc.
    • Melinta Therapeutics, Inc
    • Wellstat Therapeutics Corporation
    • Allergan
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc

第7章 市場機会および今後の動向

目次
Product Code: 64922

Market Overview

Rise in the incidence of genitourinary diseases and infections has led to the growth of the genitourinary drugs market globally. Rising disposable incomes and constant improvements in healthcare infrastructure, increase in investments on R&D activities in developing novel molecules for the treatment of genitourinary diseases and increasing number of pipeline drugs are also driving the market in the forecast period. However, an increasing number of counterfeit drugs and lack of awareness about the infections and drugs for the treatment are going to restrain the market for Genitourinary Drugs.

Scope of the Report

Genitourinary tract agents are medicines, which are used to treat conditions of the reproductive organs and excretory system or urinary tract. The term "genitourinary" actually refers to two different systems. Urinary refers to the system responsible for removal of nitrogenous waste products of metabolism from the bloodstream, disposal of concentrated wastes (urine), and also water conservation. Genito refers to the genital organs and the reproductive system, which is responsible for the production of succeeding generations for the perpetuation of the species. The genitourinary (GU) system may be affected by congenital abnormalities, inflammation, infection, other body systems or diseases of the kidneys.

Key Market Trends

Urinary Tract Infections to dominate the Global Genitourinary Drugs Market

As there is an increase in the incidence of urinary tract infections, the demand for drugs increases which in turn is driving the global urinary tract infection therapeutics market. Furthermore, the launch of combination drugs, development, and approval of new drugs which are more efficient, and the increasing geriatric population are also expected to boost the growth of the urinary tract infection segment in Global Genitourinary Drugs Market. For instance, in August 2017: FDA approved Vabomere for adults. Vabomere is an antibacterial drug, which is used for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis (a type of kidney infection caused by specific bacteria). Vabomere contains meropenem and vaborbactam. December 2017: FDA accepted the review of NDA (New Drug Application) submitted by Achaogen for plazomicin to treat cUTI including pyelonephritis and bloodstream infections (BSI), and has set a target action date under Prescription Drug User Fee Act (PDUFA) for June 2018.

The Asia Pacific is expected to be the fastest growing region

Asia is expected to experience a high growth rate in the genitourinary drugs market in the next few years due to rise in genitourinary disease cases, growing need for improved treatments and therapies of genitourinary diseases, increasing awareness about genitourinary diseases, rise in health care expenditure and developing health care infrastructure in the region. Growing demographics and economies in the developing countries, such as India and China, are expected to lead to the rise of the genitourinary drugs market in the Asia Pacific region.

Competitive Landscape

The global genitourinary drugs market displays high competition among market players. Major market players are investing high capitals on R&D and generating many strategies such as new product launches and developments, geographical expansions, collaborations and acquisitions to strengthen their market position in the global genitourinary drugs market. For instance, in September 2018: TherapeuticsMD, Inc. launched Imvexxy (estradiol vaginal inserts). for treatment of moderate-to-severe dyspareunia. Major Players in global genitourinary drugs market include Bristol-Myers Squibb Co., Eli Lilly and Company, GlaxoSmithKline, Achaogen, Inc., Melinta Therapeutics, Inc, Wellstat Therapeutics Corporation, Allergan, Merck & Co., Inc., Novartis AG, and Pfizer, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Genitourinary Disorders
    • 4.2.2 Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure
    • 4.2.3 Increasing Pipeline Products
  • 4.3 Market Restraints
    • 4.3.1 Lack of Therapy Compliance
    • 4.3.2 Increasing Advent of Counterfeit Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease Type
    • 5.1.1 Erectile dysfunction
    • 5.1.2 Gonorrhoea
    • 5.1.3 Genital Herpes
    • 5.1.4 Urinary Tract Infections
    • 5.1.5 Urinary Incontinence
    • 5.1.6 Glomerulonephritis
    • 5.1.7 Chronic renal failure
    • 5.1.8 Others
  • 5.2 By Drug Type
    • 5.2.1 Harmonal Therapy
    • 5.2.2 Impotence agents
    • 5.2.3 Uterine relaxants
    • 5.2.4 Urinary antispasmodics
    • 5.2.5 Urinary pH modifiers
    • 5.2.6 Uterine stimulants
    • 5.2.7 Miscellaneous genitourinary tract agents
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bristol-Myers Squibb Co.
    • 6.1.2 Eli Lilly and Company
    • 6.1.3 GlaxoSmithKline
    • 6.1.4 Achaogen, Inc.
    • 6.1.5 Melinta Therapeutics, Inc
    • 6.1.6 Wellstat Therapeutics Corporation
    • 6.1.7 Allergan
    • 6.1.8 Merck & Co. Inc.
    • 6.1.9 Novartis AG
    • 6.1.10 Pfizer Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top